药房购买Eczacba-Monrol,以扩大Lutetium-177生产和全球PET网络。 Curium Pharma buys Eczacıbaşı-Monrol to expand Lutetium-177 production and global PET network.

Curium Pharma 收购了 Eczacıbaşı-Monrol Nuclear Products Co.，以提高其镥 177 的产量并扩大其全球 PET 业务。 Curium Pharma has acquired Eczacıbaşı-Monrol Nuclear Products Co. to boost its Lutetium-177 production and expand its PET footprint globally. 这笔交易增强了的生产能力,为即将到来的Lu-177前列腺癌和神经内分泌肿瘤药物治疗提供了供应。 The deal enhances Curium's manufacturing capacity, securing supply for upcoming Lu-177 drug treatments for prostate cancer and neuroendocrine tumors. 它还在Curium现有的34个PET地点之外增加了东欧和中东和北非的12个新地点,改善其全球覆盖面和综合生产能力。 It also adds 12 new sites in Eastern Europe and MENA to Curium's existing 34 PET sites, improving its global reach and integrated production capabilities.